GenSight Biologics Announces Publication of Indirect Comparison of LUMEVOQ® Versus Natural History in ND4-LHON Patients in Peer-Reviewed Journal Ophthalmology and Therapy

GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ®

Biotech Outsourcing Strategies (BOS) 2021, Virtual

GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ® versus Natural History in Frontiers in Neurology

KOL Webinar on the Nature Medicine Case Report: Visual Recovery after GS030 Optogenetic Treatment

GenSight Biologics Announces Nature Medicine Case Report Showing Visual Recovery after GS030 Optogenetic Treatment

GenSight Biologics to Present Data on GS010 and GS030 at the 2017 Congress of the European Society of Gene & Cell Therapy

GenSight Biologics to Present GS010 at the 4th Annual Retinal Cell & Gene Therapy Innovation Summit